Literature DB >> 7340985

A comparative assessment of the in vitro effects of drugs on cells by means of colony assays or flow microfluorimetry.

B T Hill, R D Whelan, H T Rupniak, L Y Dennis, M A Rosholt.   

Abstract

The effects of a range of anticancer drugs on murine neuroblastoma cells, used as a readily reproducible model system, have been compared by means of colony-forming assays and analyses by flow microfluorimetry (FMF). FMF provides the most rapid means of assessing the kinetic effects of drugs on cells. However, interpretation of these data is not clear-cut, since drug effects are highly dose-dependent and no distinction can be made easily between progression arrest and cell kill. Thus whilst FMF allows some qualitative assessment of the perturbing effects of cytotoxic drugs quantitative evaluation of cytotoxicity is still dependent on data from the more time-consuming cloning assays. However, when cells are treated with certain drugs, e.g., methotrexate, vincristine, or VM26, for only 1 h, negligible kill occurred as measured by colony formation. Therefore it appears necessary to prolong in vitro exposure time when testing these drugs or evaluating cytotoxicity of potential antitumour agents in vitro.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7340985     DOI: 10.1007/bf00258208

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  Flow microfluorometric estimation of G1 and G2 chalone inhibition of the JB-1 tumour cell cycle in vitro.

Authors:  N M Barfod
Journal:  Exp Cell Res       Date:  1977-11       Impact factor: 3.905

2.  Comparison of in vitro methods to determine drug-induced cell lethality.

Authors:  P R Roper; B Drewinko
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

3.  Cell-cycle analysis in 20 minutes.

Authors:  H A Crissman; R A Tobey
Journal:  Science       Date:  1974-06-21       Impact factor: 47.728

4.  Methods and applications of flow systems for analysis and sorting of mammalian cells.

Authors:  H A Crissman; P F Mullaney; J A Steinkamp
Journal:  Methods Cell Biol       Date:  1975       Impact factor: 1.441

5.  Patterns of cell survival following treatment with antitumor agents in vitro.

Authors:  B Drewinko; P R Roper; B Barlogie
Journal:  Eur J Cancer       Date:  1979-01       Impact factor: 9.162

6.  Lethal and kinetic effects of DDMP (2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine).

Authors:  B T Hill
Journal:  Eur J Cancer       Date:  1980-01       Impact factor: 9.162

7.  In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy.

Authors:  D S Alberts; S E Samon; H S Chen; E A Surwit; B Soehnlen; L Young; T E Moon
Journal:  Lancet       Date:  1980-08-16       Impact factor: 79.321

8.  Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.

Authors:  S E Salmon; A W Hamburger; B Soehnlen; B G Durie; D S Alberts; T E Moon
Journal:  N Engl J Med       Date:  1978-06-15       Impact factor: 91.245

9.  Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining.

Authors:  A Krishan
Journal:  J Cell Biol       Date:  1975-07       Impact factor: 10.539

10.  Growth of human tumour cell colonies from biopsies using two soft-agar techniques.

Authors:  V D Courtenay; P J Selby; I E Smith; J Mills; M J Peckham
Journal:  Br J Cancer       Date:  1978-07       Impact factor: 7.640

View more
  19 in total

1.  Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion.

Authors:  F Figoli; M L Zanette; U Tirelli; R Sorio; C Lestuzzi; R Urso; S Monfardini; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 2.  Do anticancer agents reach the tumor target in the human brain?

Authors:  M G Donelli; M Zucchetti; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer.

Authors:  M Bontenbal; A S Planting; J Verweij; R de Wit; W H Kruit; G Stoter; J G Klijn
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

4.  Pharmacokinetic study of VM26 given as a prolonged IV infusion to ovarian cancer patients.

Authors:  C Rossi; M Zucchetti; C Sessa; R Urso; C Mangioni; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Kinetic and survival response of the M14 cell line to lonidamine associated with adriamycin or hyperthermia.

Authors:  G Starace; G Badaracco; A Bertuzzi; A Gandolfi; C Greco; M D Totaro; R Vitelli; G Zupi
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

Review 6.  Predictive tests in cancer chemotherapy. A reappraisal.

Authors:  R Osieka; S Seeber; C G Schmidt
Journal:  Klin Wochenschr       Date:  1984-03-01

7.  Initial and early effects of adriamycin in murine sarcoma 180 cannot be restored in a resistant subline by increasing the uptake and external concentration of the drug.

Authors:  J Sonka; U Schossig; M Vogt-Schaden; M Volm
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

8.  Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines.

Authors:  H B Niell; R F Hunter; H G Herrod; M Israel
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  Identification of synergistic combinations of spirogermanium with 5-fluorouracil or cisplatin using a range of human tumour cell lines in vitro.

Authors:  B T Hill; A S Bellamy; S Metcalfe; P J Hepburn; J R Masters; R D Whelan
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

10.  Flow-cytometric analysis of DNA distribution after VP16-213 treatment of Lewis lung carcinoma.

Authors:  E Erba; P Ubezio; T Colombo; M Broggini; L Torti; M Vaghi; M D'Incalci; L Morasca
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.